These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 3117609)

  • 21. The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype.
    Vilsbøll T; Knop FK; Krarup T; Johansen A; Madsbad S; Larsen S; Hansen T; Pedersen O; Holst JJ
    J Clin Endocrinol Metab; 2003 Oct; 88(10):4897-903. PubMed ID: 14557471
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic sulfonylurea therapy augments basal and meal-stimulated insulin secretion while attenuating insulin responses to sulfonylurea per se.
    McIntyre HD; Ma A; Bird DM; Patterson CA; Cameron DP
    Diabetes Care; 1992 Nov; 15(11):1534-40. PubMed ID: 1468283
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of weight loss and reduced hyperglycemia on the kinetics of insulin secretion in obese non-insulin dependent diabetes mellitus.
    Gumbiner B; Polonsky KS; Beltz WF; Griver K; Wallace P; Brechtel G; Henry RR
    J Clin Endocrinol Metab; 1990 Jun; 70(6):1594-602. PubMed ID: 2189885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interaction of fat-stimulated gastric inhibitory polypeptide on pancreatic alpha and beta cell function.
    Verdonk CA; Rizza RA; Nelson RL; Go VL; Gerich JE; Service FJ
    J Clin Invest; 1980 May; 65(5):1119-25. PubMed ID: 6988457
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acute actions of sulfonylurea drugs during long-term treatment of NIDDM.
    Faber OK; Beck-Nielsen H; Binder C; Butzer P; Damsgaard EM; Froland F; Hjollund E; Lindskov HO; Melander A; Pedersen O
    Diabetes Care; 1990 Aug; 13 Suppl 3():26-31. PubMed ID: 2120020
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus.
    Garvey WT; Revers RR; Kolterman OG; Rubenstein AH; Olefsky JM
    J Clin Endocrinol Metab; 1985 Mar; 60(3):559-68. PubMed ID: 3882736
    [TBL] [Abstract][Full Text] [Related]  

  • 27. KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes.
    Aaboe K; Knop FK; Vilsboll T; Vølund A; Simonsen U; Deacon CF; Madsbad S; Holst JJ; Krarup T
    J Clin Endocrinol Metab; 2009 Feb; 94(2):603-8. PubMed ID: 19050053
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in amylin and amylin-like peptide concentrations and beta-cell function in response to sulfonylurea or insulin therapy in NIDDM.
    Rachman J; Payne MJ; Levy JC; Barrow BA; Holman RR; Turner RC
    Diabetes Care; 1998 May; 21(5):810-6. PubMed ID: 9589246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glyburide decreases insulin requirement, increases beta-cell response to mixed meal, and does not affect insulin sensitivity: effects of short- and long-term combined treatment in secondary failure to sulfonylurea.
    Gutniak M; Karlander SG; Efendić S
    Diabetes Care; 1987; 10(5):545-54. PubMed ID: 2890501
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
    Clark HE; Matthews DR
    Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alterations in glucose metabolism in the elderly patient with diabetes.
    Meneilly GS; Dawson K; Tessier D
    Diabetes Care; 1993 Sep; 16(9):1241-8. PubMed ID: 8404427
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight.
    Schou JH; Pilgaard K; Vilsbøll T; Jensen CB; Deacon CF; Holst JJ; Vølund A; Madsbad S; Vaag AA
    J Clin Endocrinol Metab; 2005 Aug; 90(8):4912-9. PubMed ID: 15899957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term randomized placebo-controlled double-blind therapeutic comparison of glipizide and glyburide. Glycemic control and insulin secretion during 15 months.
    Birkeland KI; Furuseth K; Melander A; Mowinckel P; Vaaler S
    Diabetes Care; 1994 Jan; 17(1):45-9. PubMed ID: 8112188
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kinetics-effect relations of glipizide and other sulfonylureas.
    Sartor G; Melander A; Scherstén B; Wåhlin-Boll E
    Acta Endocrinol Suppl (Copenh); 1980; 239():3-5. PubMed ID: 6776762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fasting plus prandial insulin supplements improve insulin secretory ability in NIDDM subjects.
    Kawamori R; Bando K; Yamasaki Y; Kubota M; Watarai T; Iwama N; Shichiri M; Kamada T
    Diabetes Care; 1989; 12(10):680-5. PubMed ID: 2515048
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of glipizide on various consecutive insulin secretory stimulations in patients with type 2 diabetes.
    Ahrén B; Lundquist I; Scherstén B
    Diabetes Res; 1986 Jul; 3(6):293-300. PubMed ID: 3530592
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of glyburide on beta cell responsiveness to glucose in non-insulin-dependent diabetes mellitus.
    O'Meara NM; Shapiro ET; Van Cauter E; Polonsky KS
    Am J Med; 1990 Aug; 89(2A):11S-16S; discussion 51S-53S. PubMed ID: 2117385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glipizide increases plasma insulin but not C-peptide level after a standardized breakfast in type 2 diabetic patients.
    Scheen AJ; Lefebvre PJ; Luyckx AS
    Eur J Clin Pharmacol; 1984; 26(4):471-4. PubMed ID: 6376145
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect on metabolic control of second-generation sulfonylurea drugs in patients with NIDDM after secondary failure to first-generation agents.
    Sami T; Kabadi UM; Moshiri S
    J Fam Pract; 1996 Oct; 43(4):370-4. PubMed ID: 8874372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.